<DOC>
	<DOC>NCT00560313</DOC>
	<brief_summary>This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to healthy at-risk adults.</brief_summary>
	<brief_title>Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Healthy adults,18 through 50 years of age, who were or might be routinely exposed to N. meningitidis cultures Previous ascertained or suspected disease caused by N. meningitidis; Pregnancy or breastfeeding; History of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component; Any present or suspected serious acute or chronic disease Known or suspected autoimmune disease or impairment /alteration of immune function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Meningococcal disease</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
</DOC>